细胞科技一周资讯：Cartesian Therapeutics完成1.3亿美元融资 ▍ 首次！体内CAR-T疗法7月9日，Interius BioTherapeutics宣布，已获得澳大利亚治疗用品管理局（TGA）的人类研究伦理委员会（HREC）批准和临床试验通知（CTN）许可，以进行其在研体内CAR-T疗法INT2104的临床1期试验，用以治疗B细胞恶性肿瘤。Interius计划在202...
据悉，Descartes-08是一种mRNA细胞疗法候选药物，也是一种潜在“first-in-class"mRNA工程化嵌合抗原受体T细胞(mRNA CAR-T)疗法。它通过靶向BCMA，清除分泌自身抗体的浆细胞。与传统的基于DNA的CAR-T细胞疗法相比，mRNA CAR-T细胞疗法的给药设计不需要预处理化疗，而且据观察具有可预测和可控制的药代动力学，可以进行...
去年,FDA对所有在美上市CAR-T产品发出了黑框警告,因为传统的病毒DNA转染方式可能会引起DNA的随机插入而引发T细胞肿瘤的产生。 推荐阅读:CAR-T黑框警告,再起波澜 而mRNACAR-T,以mRNA为基础、不会整合到T细胞的基因体,理论上能够减少与DNA相关的毒性。 除了安全性更高,传统CAR-T治疗的另一个巨大挑战是CAR-T细胞输...
7/2,Cartesian Therapeutics 公布了其自体 mRNA CAR-T 候选药物 Descartes-08 在全身性重症肌无力 (gMG) 中的中期结果,但该公司股价下跌超过 32%,尽管一位分析师称该结果为肿瘤学以外 CAR-T 疗法领域的关键转折点。“这些数据标志着该领域的分水岭时刻,代表了 CAR-T 细胞疗法在自身免疫性疾病中的首个安慰剂...
Cartesian Therapeutics(RNAC.US)潜在“first-in-class“CAR-T疗法积极临床结果公布 智通财经APP获悉,Cartesian Therapeutics(RNAC.US)今天(7月3日)宣布了其在研mRNA细胞疗法Descartes-08在全身性重症肌无力(MG)患者中的2b期临床试验的积极顶线结果。在这项2b期双盲、安慰剂对照、交叉试验中,共有36名症状严重、...
Cartesian Therapeutics, Inc. recently announced the first patient has been dosed in its first-in-human Phase 1 trial of Descartes-15, the Company’s next-generation autologous anti-B cell maturation antigen (BCMA) mRNA-engineered chimeric antigen receptor T-cell...
Cartesian Therapeuticsis a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is an mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for sys...
July 2024. A copy of today’s presentation will be available in the Publications and Presentations section of the Company’s website. Descartes-08, Cartesian’s lead mRNA cell therapy candidate, is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) product ...
Descartes-08, Cartesian’s lead mRNA cell therapy candidate, is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) product targeting B-cell maturation antigen (BCMA) in clinical development for generalized myasthenia gravis (MG) and systemic lupus erythema...
(Cartesian and XOR). Model specificp-values for each pairwise interaction were derived by performing a t-test on the interaction term (\(\beta _3\)) assuming a null hypothesis where (\(\beta _3\)) = 0. Given the large number of tests conducted, they applied the Benjamini-Hochberg ...